fbpx

Stay Informed. Stay Competitive. Get Free Email Updates Dow 30 & Emerging Growth

Stay Informed. Stay Competitive.

Get Free Updates

Dow 30 & Emerging Growth

Large Caps Led Markets Higher This Week – $AAPL $GME $INM $NVDA $TSLA Rise!

By John F. Heerdink, Jr.
“You cannot escape the responsibility of tomorrow by evading it today.” – Abraham Lincoln


Happy Weekend All!

I hope that you all had a great week in the markets and otherwise. The markets this week were definitively led by the large caps while the growth side of the market, i.e. the small caps and especially the Microcaps faltered once again as investors tended to push toward more ‘defensive’ issues and/or as yearend tax loss selling accelerated. The markets this week were influenced by President Joe Biden’s signing of the $1.2T bipartisan infrastructure bill, the House’s positive vote for the $1.75T Build Back Better Act, the CDC advisory committee recommendation for COVID-19 booster shots for all adults,  and, of course, a number of macroeconomic reports that sprung up throughout the week. On Monday, the Empire State Manufacturing Survey report confirmed an upward move to 30.9 in November.  On Tuesday, the total retail sales report confirmed a rise by 1.7% M/M in October. The total industrial production report confirmed a rise by 1.6% in October, while the capacity utilization rate moved up to 76.4%. The NAHB Housing Market Index also rose to 83.0 in November. The business inventories report confirmed a rise by .7% M/M in September. The import prices report also showed a rise by 1.2% M/M, while export prices moved up 1.5%. On Wednesday, the October housing starts report confirmed a drop by .7% M/M to a seasonally adjusted annual rate of 1.52M units, while the Building permits report confirmed a 4% rise to 1.65M. The single-unit permits report confirmed a rise by 2.7%M/M. The weekly MBA Mortgage Applications Index report showed a drop by 2.8%. On Thursday, the Initial jobless claims report for the week ending November 13 confirmed a drop by 1k to 268k , while continuing jobless claims for the week ending November 6 fell by 129kto 2.08M. The Philadelphia Fed Index report for November also showed a rise to 39. The Conference Board’s Leading Economic Index report for October confirmed a rise to .9%.

In turn, the large caps moved higher pushing the S&P 500 to a record close of 4,697.96 (-.3%), which is now up 25.1% YTD. 8 of the 11 sectors also finished the week in the red, with the consumer discretionary sector up 3.8% the information technology sector up 2.4%, & the utilities up .9% showing strength. The energy sector down 5.2% (oil prices dropped 6%), the financials down 2.8%, & the materials sector down 2% shouldered the bulk of the decline this week. The Nasdaq also pushed to record highs and closed at 16,057.44 (+1.2%) and is now up 24.6% YTD. On the contrary, the large caps on the Dow 30 did not fair so well as it closed at 35,601.98 (-1.4%), but remains up 16.3% YTD. The small caps on the Russell 2000 fell significantly with the move to more defensive issues closing at 2,343.16 (-2.8%), but remains up 18.6% YTD. The MicroCaps joined the downward move as the iShares Micro-Cap ETF (IWC) closed at $148.99, off a whopping 4.16% for the week, but remains up 25.57% YTD. 

The yield curve’s volatility tempered to the downside this week. The 10-yr yield closed at 1.54%, down 4 basis points wk/wk and the 2-yr yield closed at .51%, down 1 basis point. 

The U.S. Dollar Index also moved higher once again this week to end at 96.03 moving up from the 95.12 mark last week ending near a multi-year high once again. 

Next week, the macroeconomic schedule will serve the personal income and credit reports, the PCE index report, & the PMI composite report.


EV, TECH, CONSUMER

Apple (AAPL) closed at $160.55, +7.04% over the last 5-days. This week, Apple® announced Self Service Repair, which will allow customers who are comfortable with completing their own repairs access to Apple genuine parts and tools. Available first for the iPhone® 12 and iPhone 13 lineups, and soon to be followed by Mac® computers featuring M1 chips, Self Service Repair will be available early next year in the US and expand to additional countries throughout 2022. Customers join more than 5,000 Apple Authorized Service Providers (AASPs) and 2,800 Independent Repair Providers who have access to these parts, tools, and manuals.

Shares of IronNet, Inc. (IRNT), an innovative leader transforming cybersecurity through Collective Defense, closed at $10.52 up +.67. Recently, IronNet announced that it has joined the Microsoft Intelligent Security Association (MISA), a nomination-only association, demonstrating IronNet’s long-term commitment with Microsoft to deliver better security solutions to customers. As a Microsoft partner, IronNet, through its innovative Collective Defense platform, empowers Microsoft customers to execute safe and seamless migrations to the cloud amidst the increasing volume of highly-aggressive and sophisticated cyberattacks. IronNet Founder and Co-CEO, General (Ret.) Keith Alexander, “As we continue to see an increase in malicious cyberattacks against both the public and private sectors, we are pleased to join the Microsoft Intelligent Security Association to advance how we defend together. MISA’s mission directly aligns with our mission at IronNet: to develop integrated and innovative ways to better defend together against an evolving cyber threat landscape.” 

EV giant Tesla (TSLA) moved higher to close at $1,137.06, +10.03% this week, while the recently doubled IPO shares of Rivian Automotive, Inc. (RIVN) closed at 128.60, down 1.04% this week. RIVN went public a week ago Tuesday at $78, is still worth an amazing $113.61B after hitting a high of $179.47.  Shares of Ford (F) closed at $19.39, -.56%. Interestingly, Ford is believed to own ~12% of Rivian’s shares now worth over +$13B. On Nov. 4, Ford Motor Company and its financing subsidiary, Ford Motor Credit Company, introduced the North America auto industry’s first sustainable financing framework, focusing on and paying for ambitious plans in vehicle electrification and other environmental and social areas. On Oct, 27, Ford Motor Company (F) reported its 2021 third quarter financial results after the markets closed. Ford generated quarterly revenue of $35.7 billion, net income of $1.8 billion, adjusted EBIT of $3.0 billion; North America auto EBIT margin of 10.1%. Ford increased guidance for full-year 2021 adjusted EBIT to between $10.5 billion and $11.5 billion & expects cash flow over current planning period to be more than sufficient to fund growth priorities; announces resumption of regular stock dividend in fourth quarter.


Shares of Microsoft Corp. (MSFT) closed at 343.11, +1.9% this week. Last week MSFT released their Q1 2022 fiscal earnings report. On November 12, Kyndryl (NYSE: KD), the world’s largest IT infrastructure services provider, and Microsoft Corp., announced a landmark global strategic partnership that will combine their market-leading capabilities in service of enterprise customers. The deal with Microsoft is Kyndryl’s first since recently becoming an independent public company and provides incremental multi-billion dollar revenue opportunities for the two companies. Together the companies will bring to market state-of-the-art solutions built on the Microsoft Cloud that will accelerate hybrid cloud adoption, modernize applications and processes, support mission-critical workloads, and further enable modern work experiences for customers.

NVIDIA (NVDA) closed $329.85 jumping another 8.54% this week as they reported Q3 earnings post the close on Wednesday.  NVDA handily beat expectations clocking in with revenue at $7.1B vs. $6.81B expected, earnings per share was $1.17 vs. $1.11 expected, gaming revenue came in at $3.22 billion vs.$3.18B expected, & the Data Center revenue was at $2.94B vs. $2.69B that was expected.

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $113.24, -4.43% for the week.

The Technology Select Sector SPDR Fund (XLK) closed at $171.31, +2.39% for the week.

Disney (DIS) closed at $154, -3.53% for the week.  On Monday, Disney launched Mickey and Friends Stay True: Stay-Cation, a nationwide campaign inspired by Mickey and Friends (otherwise known as the Sensational Six) and their passions for food, arts & fashion, and pets & play. Through six exciting and immersive city guides fans will be able to enjoy their city through a new lens. Last week, Disney reported earnings for its fourth quarter and fiscal year ended October 2, 2021 which missed expectations. Diluted earnings per share (EPS) from continuing operations for the quarter was income of $0.09 compared to a loss of $0.39 in the prior-year quarter. Excluding certain items(1), diluted EPS for the quarter was income of $0.37 compared to a loss of $0.20 in the prior-year quarter. Diluted EPS from continuing operations for the year ended October 2, 2021 was income of $1.11 compared to a loss of $1.57 in the prior-year. Excluding certain items(1), diluted EPS for the year increased 13% to $2.29 from $2.02 in the prior-year. “This has been a very productive year for The Walt Disney Company, as we’ve made great strides in reopening our businesses while taking meaningful and innovative steps in Direct-to-Consumer and at our Parks, particularly with our popular new Disney Genie and Magic Key offerings,” said Bob Chapek, Chief Executive Officer, The Walt Disney Company. “As we celebrate the two-year anniversary of Disney+, we’re extremely pleased with the success of our streaming business, with 179 million total subscriptions across our DTC portfolio at the end of fiscal 2021 and 60% subscriber growth year-over-year for Disney+. We continue to manage our DTC business for the long-term, and are confident that our high-quality entertainment and expansion into additional markets worldwide will enable us to further grow our streaming platforms globally.”

Shares of McDonald’s (MCD) closed at $251.95, +.51% for the week. McDonald’s President and Chief Executive Officer, Chris Kempczinski recently recently stated, “Our third quarter results are a testament to our unparalleled scale and agility. Our global comparable sales increased 10% over 2019, which was delivered across an omnichannel experience that is focused on meeting the needs of our customers. We continue to execute our strategic growth plan and run great restaurants so that we can drive long-term, sustainable growth for all of our stakeholders.” Global comparable sales were up 12.7% in the third quarter and increased 10.2% on a 2-year basis & Year-to-date digital Systemwide sales* were about $13 billion, or over 20% of total Systemwide sales in our top six markets.

BIOTECH & HEALTHCARE

 The Nasdaq Biotechnology ETF (IBB) closed at $154.56, +.36% for the week, now up 2.03% YTD. The NYSE ARCA Biotech Index (^BTK) closed at 5,426.56, -.19% for the week and is now down -5.44% YTD. The SPDR S&P Biotech ETF (XBI) closed at $121.92, -3.65% for the week and is off -13.4% for the year. The XBI’s 52-wk range is $118.23-$174.79.  The small stocks in this sector are definitely being hurt the most this year to say the least.

Recently,  Atossa Therapeutics (ATOS) released a short video message recognizing Breast Cancer Awareness Month, and urging women to get mammograms. In the video message, which can be found on Atossa’s website here, Dr. Quay cites that the global pandemic “changed everything” with regard to breast cancer screening, indicating that many women have ceased to seek out their mammograms since the initial COVID-19 outbreak. This is corroborated in an article in the October 2021 issue of the peer-reviewed medical journal, Preventative Medicine, which indicated this was a particular problem in women of color and those who fall in the lower income brackets. On October 23, Dr. Steven Quay CEO of Atossa Therapeutics (NASDAQ: ATOS) published an interesting and informative video called “Long COVID Is An important Issue.” You may view by clicking here now.

I hosted a FREE Tribe Public Presentation and Q&A event with INMB management on September 30, 2021. INmune Bio’s (NASDAQ: INMB) CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss delivered their presentation titled “Improving White Matter Integrity In Alzheimer’s Disease” & and were available for a brief Q&A session. Please view the video that has now been viewed over 30k times to learn more now.


Health Care Select Sector SPDR (XLV) moved up this week to close at $132.97, -.63% over the last 5-days. 

GOLD & SILVER MOVE HIGHER

Gold prices closed at $1,849, -$18 for the week & silver prices closed at $24.67, -$.63/oz. for the week. Hecla Mining (HL) closed at $6.03, -6.03% for the week. First Majestic (AG) closed at $12.88, -7% for the week. 

MEMES REPORT

AMC Entertainment (AMC) closed at $40.87, +2.18% over the last 5-days. On Nov. 12, Dreamscape, the location-based immersive virtual reality company,  announced it will open its next venue in Paramus, New Jersey, Dreamscape at AMC Garden State, at the Westfield Garden State Plaza on November 19, 2021. Launched in partnership with AMC Theatres®, Dreamscape will be located within the AMC Garden State 16 theatre. Serving the greater New Jersey and New York metro area, audiences can purchase advanced tickets for the location from dreamscapeimmersive.com. On November 8, AMC reported results for the third quarter ended September 30, 2021. AMC operated 596 domestic theatres representing essentially 100% of its domestic theatres and 351 international theatres representing approximately 99% of its international theatres. Substantially all of the Company’s theatres were open for the entirety. 

GameStop (GME) closed at $228.80, +13.21% for the week. On Nov. 4, GameStop announced that it has entered into a new $500 million global asset-based revolving credit facility (“ABL Facility”) with a syndicate of banks. The new five-year ABL Facility, which was oversubscribed, replaces the Company’s existing $420 million facility due in November 2022. In addition to delivering enhanced liquidity, the new ABL Facility provides for reduced borrowing costs, lighter covenants and more flexibility. Wells Fargo Bank, N.A. acted as Lead Arranger and will serve as Administrative Agent.

Bed Bath & Beyond Inc. (NASDAQ: BBBY) announced recently that it expects to complete its $1 billion three-year share repurchase plan by the end of fiscal 2021, two years ahead of schedule. Shares of BBBY closed at $23.25, +3.25% for the week. 

Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) closed at $.9401, -9.6% for the week. Seaenergy recently its financial results for the third quarter ended September 30, 2021. Highlights of the Third Quarter of 2021: Gross revenues: $50 million in Q3 2021, as compared to $20.4 million in Q3 2020, up 146%, Net Income: $20.1 million in Q3 2021, as compared to $3.6 million in Q3 2020, up 459%, EBITDA1: $30.1 million in Q3 2021, as compared to $12.7 million in Q3 2020, up 137%, Adjusted EBITDA1: $32.2 million in Q3 2021, as compared to $7.8 million in Q3 2020, up 312%.

BITCOIN

Bitcoin $BTC.X closed at $58,933.15, -2004% this week.

ENERGY

The Energy Select Sector SPDR Fund or ETF (XLE) closed at $54.67, -5% over the last five days & +44.25% YTD. 

NEXT WEEK

The stock market will enjoy another normal 5-day trading week.

VP WATCHLIST UPDATES

Please review our complete VP Watchlist that includes Apple (AAPL), Disney (DIS), Tesla (TSLA) & a select group of emerging names.  The pages will allow you to learn more and keep up with these companies daily.

For now, see the summaries or five of the emerging companies from the VP Watchlist below:


  • Shares of INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, closed at $13.37, -7.92% this week. The 52-wk range is $7.28 – $30.37.
    • Last week, INMB presented multiple poster presentations and a plenary talk at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting that was held from November 9-12 in Boston. Learn more. 
    • The Maxim Group’s analyst Jason McCarthy confirmed his $42 Price target recently.  
    • On Nov. 3rd, INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, reported its financial results for the third quarter ended September 30, 2021 and provided a business update including the announcing of a second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer’s disease (AD) & Cash and cash equivalents of $84.5 million on September 30th. RJ Tesi, M.D., Chief Executive Officer of INmune Bio stated, “In the first patient treated in our Phase I study of INKmune™ in high-risk myelodysplastic syndrome, INKmune™ was found to safely produce cancer killing memory-like NK cells while increasing proliferation and persistence of those NK cells. As expected, the memory-like NK cells generated in vivo killed NK-resistant cancer cells in vitro. We now have data from Day 73 post first treatment and over 60% of his peripheral blood NK cells remained activated and highly functional in vitro. We are continuing to screen patients for future enrollment and are in the process of expanding the number of clinical trial sites in the UK and overseas. Our latest drug stability data allows us to extend the shelf-life to over 12 months and consequently we initiated a manufacturing scale up to secure drug supplies as the program expands. In our Phase I trial of XPro in AD, we have shown that XPro decreases biomarkers of neuroinflammation and neurodegeneration while improving biomarkers of CNS repair. We hope to demonstrate these effects on cognition in the Phase II mild AD trial that is on track to initiate later this year.” INmune Bio announced that they will deliver multiple poster presentations and a plenary talk at the upcoming 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting that is being held during November 9-12 in Boston. For details please visit the following link. 
  •  
    • I hosted a FREE Tribe Public Presentation and Q&A event with INMB management, Thursday, September 30 at 8:30am PT/11:30am ET. INmune Bio’s (NASDAQ: INMB) CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss delivered their presentation titled “Improving White Matter Integrity In Alzheimer’s Disease” & and were available for a brief Q&A session. Please view the video that has been viewed over +30k times now to learn more.

    • On Wednesday, Aug. 4th, INmune Bio, Inc. reported its financial results for the second quarter ended June 30, 2021 and provided a business update. Raymond J Tesi, M.D., CEO/CMO of INmuneBio (INMB) stated, “We continue our planning and setup for a Phase 2 clinical trial of our lead candidate, XPRO™ (Xpro1595™), in patients with mild Alzheimer’s disease, which we plan to initiate by year-end. We have already demonstrated that XPRO™ can reduce neuroinflammation and decreases biomarkers of neurodegeneration and improve synaptic function. If successful in Phase 2, we believe XPRO™ has the potential to be among the most significant advancements in the treatment of Alzheimer’s Disease (AD) and other neurodegenerative diseases in many years. At the Alzheimer’s Association International Conference last week, we introduced a new biomarker – Apparent Fiber Density (AFD), a measure of axonal integrity measured by MRI. XPRO™ increases AFD in patients receiving 1mg/kg/week. We believe the novel non-invasive white matter analytics of white matter free water and apparent fiber density will be very useful in the development of XPRO™ in AD, Treatment Resistant Depression (TRD) and the many other CNS indications we hope to attack in the future. Last month, we treated the first patient in the first Phase 1 clinical trial of our NK cell priming platform, INKmune, in high-risk myelodysplastic syndrome (MDS). We are calling INKmune a pseudokine because, in vitro, it converts the resting NK cells into memory-like NK cells that can kill cancer cells as well or better than NK cells treated cytokines such as IL-12, IL-15 and IL-18 alone or in combination.”
    • On July 26th, INmune Bio announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD) at AAIC. The announcement was accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients. READ MORE. 
    • On July 22, LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced that it has installed its ground-breaking z-Movi® Cell Avidity Analyzer at INmune Bi0. INmune Bio is employing the z-Movi cell avidity analysis platform to demonstrate that the mechanism of action of the tumor-priming is the increase in NK cell:tumor cell avidity. Early data acquired by the z-Movi support their hypothesis that increased cell avidity enhances NK cell killing of tumor cells. This allows screening of batches of INKmune for potency and provides a potential biomarker of in vivo activity by measuring the tumor avidity of NK cells isolated from patients before and after INKmune treatment.
    • On July 14th, INmune Bio announced that it has entered into a definitive agreement with one healthcare focused institutional investor and one family office for the purchase and sale of 1,818,182 shares of its common stock at a price of $22 per share for gross proceeds of approximately $40 million in a registered direct offering. The closing of the offering is expected to occur on or about July 16, 2021, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. INmune Bio intends to use the net proceeds from this offering for working capital and general corporate purposes and to advance the development of its product candidates and expand its pipeline. This includes the completion and data readout from the Company’s planned Phase 2 clinical trial of its lead clinical candidate, XPro1595, in patients suffering from Alzheimer’s disease, which is expected to commence by the end of 2021. “With this investment, we expect the Company’s Phase II program in Alzheimer’s disease is completely funded said RJ Tesi MD, CEO of Inmune Bio.
    • On July 12th,  INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase 1 clinical trial of its Natural Killer (NK) cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome (MDS). This Phase 1 open label study will enroll nine patients with a confirmed diagnosis of MDS with excess blasts in a 3×3 dose escalation protocol. The primary endpoint is the safety and tolerability of INKmune when administered intravenously. Most secondary endpoints are biomarkers and include the change in percentage of blasts in peripheral blood and bone marrow, the change in autologous NK cell activity and functional maturity into tumor-induced memory-like NK cells in vivo. The overall response rate using WHO criteria, and duration of response will also be reported. READ MORE.
    • On June 14th, INMB announced that it had entered into a new $15M credit facility with Silicon Valley Bank (SVB) and an affiliate of SVB Financial Group. INmune intends to use the proceeds from the facility to partially fund the buyout of an option held by Xencor, Inc.(XNCR), resulting from INmune’s in-licensing of XPro1595 (now known by its generic name, pegipanermin) in October 2017. XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that uses a dominant-negativeTNF technology that is very different from approved TNF inhibitors that block the effects of both soluble and trans-membrane TNF. Pegipanermin neutralizes soluble TNF, without affecting trans-membrane TNF or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s and other neurodegenerative diseases by decreasing neuroinflammation. Total consideration to be paid to Xencor by INmune is $18.3 million, comprised of $15 million of cash and $3.3 million of INMB shares at a price of $17.14 resulting in the issuance of 192,533 shares. Pursuant to the original 2017 in-licensing agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of INmune’s fully diluted company shares for a period of seven years. The retirement of the Xencor option eliminates an estimated 2.1 million shares of potential future common stock dilution upon exercise of the option.



  • Shares of InMed Pharmaceuticals, Inc. (NASDAQ: INM), a leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids, closed at $1.82, +30% this week after reaching $2.37 intraday trading and seeing 141 million share trading day.
    • Please visit the INM page at our website to learn more and check out the videos section too. The 52-wk range is $1.2545 – $8.94. 
    • On November 10, InMed announced their financial results for the first quarter of fiscal year 2022 which ended September 30, 2021. “The first quarter of fiscal 2022 saw positive momentum across all of our programs,” says Eric A. Adams, InMed President & CEO. “With the completion of the BayMedica Inc. (“BayMedica”) acquisition, our integrated teams are working together to identify rare cannabinoids in BayMedica’s pipeline for commercialization in the consumer health and wellness industry. For the duration of fiscal year 2022, we will be focused on growing revenues through the launch of these selected rare cannabinoids, in addition to expanding sales of BayMedica’s Prodiol® CBC (cannabichromene) and progressing our existing programs.”
    • On October 13, InMed announced that they have completed the previously announced acquisition of BayMedica Inc. (“BayMedica”), a private company based in the US specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector. Eric A. Adams, President and Chief Executive Officer of InMed, stated, “We are delighted to close this acquisition and welcome everyone at BayMedica to the InMed team. In the next several weeks, we will focus on corporate integration, exploring our combined manufacturing know-how and looking to accelerate revenue growth. BayMedica brings significant expertise and will help strengthen our pharmaceutical drug development efforts as well as position the Company to become a global leader in the manufacturing of rare cannabinoids.”
    • On September 30, INmed announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease. This study will be taking place at eleven sites across seven countries including Austria, Germany, Greece, France, Italy, Israel and Serbia. Clinical Trial Applications (“CTAs”) have been filed in all participating countries with regulatory authority and ethics committee approvals currently in place in four countries (Austria, France, Greece, Israel). The first site initiation visit was completed at a clinical site in Austria, where screening for eligible patients will begin shortly. “The start of this Phase 2 clinical trial represents a very important step forward to test the efficacy of INM-755 (cannabinol) cream in treating epidermolysis bullosa, a disease that has very few treatment options,” stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed. “Based on our earlier studies, we are hopeful that our cannabinol cream will prove to be a safe and effective treatment for people living with this severe genetic skin disease.”
    • On July 9th, Roth Capital Partners analyst Scott Henry, CFA issued an update report with. BUY Rating titled, “INM: Favorable Take on BayMedica LOI” that includes a $11.50 12-Month Price Target.


  • Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $55.97, +.21% over the last 5-days. 
    • On Nov 4, FATE reported business highlights and financial results for the third quarter ended September 30, 2021. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “The interim Phase 1 data from our FT516 and FT596 programs in relapsed / refractory lymphoma demonstrate that our off-the-shelf, iPSC-derived NK cell product candidates have the potential to deliver substantial therapeutic benefit for patients along with a differentiated safety profile that supports outpatient treatment. We look forward to sharing additional clinical data from both of these programs at the American Society of Hematology Annual Meeting in December. We also continue to be pleased with the clinical advancement of our multiplexed-engineered, iPSC-derived NK cell pipeline, where we have now successfully treated the first patients with FT516 in disease-specific expansion cohorts for lymphoma and with FT538 in combination with daratumumab for multiple myeloma. Additionally, we have successfully completed GMP manufacture and release of FT576, our multi-antigen targeted, CAR BCMA product candidate for multiple myeloma, and have initiated enrollment in our Phase 1 study.”
    • On Oct. 1, Fate announced that one oral and four poster presentations for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021. The oral presentation will highlight preclinical data for FT536, the Company’s off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate that uniquely targets the α3 domain of the MHC class I related proteins A (MICA) and B (MICB). In a recent publication in Cancer Immunology Research (DOI: 10.1158/2326-6066.CIR-19-0483), Kai W. Wucherpfennig, M.D., Ph.D., Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and co-leader of the Cancer Immunology Program at Dana-Farber / Harvard Cancer Center, demonstrated that cancers with loss of MHC Class I expression can be effectively targeted with MICA/B α3 domain-specific antibodies to restore NK cell-mediated immunity against solid tumors. The FT536 program is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics. The Company expects to submit an Investigational New Drug (IND) application for FT536 in the fourth quarter of 2021 for the treatment of advanced solid tumors, including in combination with monoclonal antibody therapy.
    • On September 15, Fate Therapeutics announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell product candidate FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells. The superior anti-tumor activity of FT538 was attributable to its novel engineered components, including the knockout of CD38 and the expression of IL-15/IL-15R fusion protein, which were shown to improve metabolic fitness, increase resistance to oxidative stress, and induce transcription of proteins that control NK cell activation and effector function. The data were published in Cell Stem Cell in an online article entitled “Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy”.


  • Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at closed at $2.35, 11.32% this week. 
    • On Nov. 15, Atossa announced their financial results for the fiscal quarter ended September 30, 2021, and provided an update on recent company developments. Dr. Steven Quay, Atossa’s President and Chief Executive Officer stated, “Our progress in both the Endoxifen and COVID-19 programs, with our initiation of our trial in Australia for AT-H201, and our receipt of regulatory authorization in Sweden to commence an Endoxifen Phase 2 trial, have been key recent milestones, positioning us to move both of these programs forward and take the next steps toward developing therapies in urgent unmet patient needs. Further, our strong balance sheet will continue to facilitate our development plans as we not only execute on these trials but also explore additional options that could create significant shareholder value,” Review the balance of the story here. 
    • I will host Atossa Therapeutics’ CEO Dr. Steven Quay, MD, PhD & CFO Kyle Guse at a Tribe Public Event titled, “A Town Hall Q&A Event With Atossa Therapeutics Management Team” on Tuesday, November 30 at 8 am PT/ 11am ET. Please register now at ATOSQA.TribePublic.com
    • On October 23, Dr. Steven Quay CEO of Atossa Therapeutics (NASDAQ: ATOS) published an interesting and informative video called “Long COVID Is An important Issue.” You may view by clicking here now.
    • On September 30, September 30, Atossa announced it has begun to enroll participants in its clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. “Even with vaccines becoming widely available, the COVID-19 pandemic continues to be an urgent global health crisis,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “Enrolling the first two participants in this study marks a significant milestone in our goal of ultimately developing nebulized AT-H201 to improve lung function in patients with active disease, which may reduce the number of patients requiring ventilators, and in ‘long-haul’ patients who have residual pulmonary function damage. Up to one third of hospitalized patients have pulmonary function changes 60 days or more after recovering from COVID. The portability of nebulizers, already routinely used for other chronic lung disease, should allow for treatment at home.”
    • On September 8th, Edward Woo, analyst at Ascendiant Capital Markets issued an update report titled “Q2 about inline. COVID-19 and breast cancer clinical trials expected to start soon should be catalysts for stock” and raided his P/T to $8.50.
    • On Aug 13th, Atossa announced financial results for the fiscal quarter ended June 30, 2021, and provided an update on recent company developments. “We continue to experience encouraging progress in our MBD and COVID-19 programs, with new regulatory approvals being granted in Sweden for a Phase 2 trial in MBD and authorization in Australia to commence a Phase 2 study of AT-H201 for respiratory illness associated with COVID-19. In the meantime, we continue to enjoy a strong balance sheet, which we have significantly expanded over the last three quarters and will facilitate our development plans over the near term. As we actively explore the possibility for strategic expansion into other areas where we might see near-term milestones and results, we also urge all of our shareholders to exercise their right to vote at our special stockholder’s meeting on September 7, 2021. We urge a vote in favor of the proposal to increase authorized shares, which will provide the Company with the flexibility to issue shares as part of these potential acquisitions, collaborations and partnerships, a common strategy successful biotech companies seeking to grow shareholder value employ in order to create a more attractive opportunity for all. We look forward to continuing to update our stockholders on these opportunities as they develop,” stated Dr. Steven Quay, Atossa’s President and Chief Executive Officer.
  •  

  • Shares INVO Bioscience (NASDAQ: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $2.95.  
    • On Nov 16, Colliers Secuirites issued an update report titled “Dedicated INVOcell Clinics To Begin Meaningful Sales in CY22. Decision On 5-Day label Expansion Expected in 1Q22.” The report carried a BUY rating on INVO and a Price Target of $6.
    • On Nov. 15, INVO announced their financial and operating results for the third quarter ended September 30, 2021, and provided a business update. Steve Shum CEO of INVO stated , “We continue to execute against our core mission of improving access to advanced fertility services for the many patients around the world through the use of the INVOcell solution. During the quarter, we achieved a significant milestone with the opening of our very first INVO Center, based in Birmingham, where we have commenced initial cycles. Further, we opened clinics in Atlanta, Georgia and Monterrey, Mexico to expand the INVO Center business model and we are working to open the San Francisco Bay Area clinic as soon as possible. We completed the acquisition of a Canadian-based entity that will be used to distribute the INVOcell in Canada and to develop INVO Centers in the region. With our INVO Center strategy now successfully underway, we are optimistic on the prospects for further expansion using this unique and innovative model. As part of a detailed review, we have initially identified more than 20 cities here in the U.S. that we believe have excellent characteristics in terms of demographics and level of current fertility care that would be ideal locations for an INVO Center.” READ the balance of the story here. 
    • On Nov. 8 after the market closed, INVO announced that it will regain full U.S. commercialization rights for its patented INVOcell® device due to Ferring International Center S.A.’s termination for convenience of that certain Distribution Agreement dated November 12, 2018 with INVO, which termination will officially take effect on January 31, 2022. Over the past three years, INVO has been executing on a multi-faceted commercialization strategy which includes partnering to open dedicated “INVO Centers” focused on INVOcell and the IVC procedure, and establishing agreements with distributors in key markets. The terms of the U.S. Distribution Agreement had limited the number of INVO Centers that we were allowed to operate. INVO can now further support U.S. fertility clinicians directly as the exclusive provider of INVOcell® in pursuit of our mission to bring advanced fertility care to the millions of people that are without access to treatment.
    • On October 20, INVO Bioscience, Inc. announced that four exciting poster abstracts were presented discussing INVOcell at the 77th Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) being held this week in Baltimore, Maryland. “It’s extremely rewarding to see our technology highlighted at this year’s ASRM. Four independent abstracts were selected for presentation at the fertility industry’s most prominent annual meeting. On behalf of the entire INVO team, we sincerely appreciate the work of the many clinicians that now support INVOcell as a solution and thank those that contributed their independent work in advancing the understanding of the unique capabilities of INVOcell. These types of events and studies emphasize the opportunity we have to democratize advanced fertility services through the unique attributes of the INVOcell solution and bring care to the large, underserved patient population around the world,” stated Steve Shum, CEO of INVO Bioscience. LEARN MORE! 
    • On Oct. 1, INVO announced that it has entered into definitive agreements with institutional and accredited investors and members of INVO Bioscience’s management team to purchase 1,240,763 shares of its common stock at a purchase price of $3.26 per share, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $4.0 million. The registered direct offering is expected to close on or about October 5, 2021, subject to the satisfaction of customary closing conditions.
      • The group of investors includes members of INVO Bioscience’s management team, including Steve Shum, CEO, and Andrea Goren, CFO. Paulson Investment Company, LLC is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $4.0 million, before deducting placement agent’s fees and other offering expenses. INVO Bioscience currently intends to use the net proceeds from this registered direct offering for general corporate and working capital purposes.
      • Also, on Oct. 1, INVO entered into a separate Stock Purchase Agreement with Paradigm Opportunities Fund, LP an accredited institutional investor, pursuant to which we will issue to such investor 600,703 shares of their common stock, par value $0.0001 per share for a purchase price of $3.329 per share for an aggregate purchase price of $1,999,740.29. This transaction is set to close on November 30, 2021. The Shares will be issued under the exemption from registration under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933, as amended. The Purchase Agreement contains a $250,000 break-up fee whereby if either party fails to close, it will be required to pay the non-breaching party a fee of $250,000. The investor under the Purchase Agreement also agreed to a 1-year lock up period with respect to the Shares.
    • On September 9th, INVO Bioscience announced that it has completed the acquisition of a Canadian-based entity that was originally formed to offer INVOcell in Canada. The entity had previously completed a number of important procedures and documentation necessary to establish INVOcell within clinical operations in Canada. INVO Bioscience anticipates leveraging this entity to advance the distribution of INVOcell, and take advantage of the existing product registration which approved the device for sale based on 5-day incubation in the Canadian market. In addition, the Company is initiating the development of joint ventures to establish INVO Centers within the Canadian marketplace, similar to U.S. and Mexico markets, to further drive accelerated adoption of the INVOcell solution while also increasing much needed capacity and patient access within the fertility industry. Steve Shum, CEO of INVO Bioscience, commented, “We believe Canada offers an excellent opportunity to further expand our distribution efforts of INVOcell while also advancing our joint-venture based INVO Center model. With roughly 16% (or 1 in 6) couples in Canada experiencing infertility, a number that has doubled since the 1980s, and with a popultion of 37.74 million, Canada represents a sizable market opportunity. Canada also faces similar issues that hamper other parts of the world, including a large underserved population, access/capacity constraints and affordability challenges. We appreciate the key individuals in Canada that originally created this entity to help promote and bring our INVOcell technology into the marketplace and look forward to bringing greater resources to advance this effort. We anticipate this acquisition will serve as a platform to help accelerate building INVOcell’s presence in Canada.”
    • On September 7th,  INVO Bioscience announced that it has officially opened the Company’s 2nd INVO Center in the United States, based in Atlanta, Georgia after recently opening their first in Birmingham, AL called “Innovative Fertility Specialists, An INVO Center” on August 9th. INVO Centers are further scheduled this year to open in Monterrey, Mexico & the San Francisco Bay Area. This new joint-venture, named “Bloom Fertility, an INVO Center,” will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution. READ THE COMPLETE STORY. 

    • On August 16th, INVO announced their financial and operating results for the second quarter ended June 30, 2021 and provided a business update. Steve Shum , CEO of INVO stated. “Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week’s official opening of our first INVO Center practice in Birmingham, AlabamaWe feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years. We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need.”
    • On Aug.2, INVO announced the Company’s first Joint Venture INVO Center practice in the United States, based in Birmingham, Alabama, will officially open on August 9, 2021. Dr. Hammond commented, “With the opening of the country’s first INVOcell medical practice, we are advancing a core mission towards improving access to advanced fertility services for the many patients who would otherwise never have the opportunity. To date, we have already received numerous advanced inquiries via word of mouth and have dozens of patients scheduled for initial patient consultations who are eager to proceed with treatment. As we officially open the center next week, we expect to accelerate our marketing programs with the help of the INVO marketing team to enhance overall patient awareness around Innovative Fertility Specialists, An INVO Center.”

INVO

    • On June 30th, VP Watchlist company, INVO Bioscience, Inc. (NASDAQ: INVO) expanded their North American footprint as they announced on June 30th that they had signed a joint venture agreement in partnership with reproductive specialist Dr. Sue Ellen Carpenter, M.D. through its wholly-owned subsidiary, INVO Centers, LLC, to open an INVO clinic in Atlanta. The clinic, Bloom Fertility, is scheduled to open in the second half of 2021. INVO Bioscience will provide funding for start-up and operating costs and own 40% of the Atlanta Joint Venture. Dr. Sue Ellen Carpenter, MD, is Board Certified in Obstetrics and Gynecology. With over 30 years of experience in reproductive medicine, Dr. Carpenter’s specialties include in vitro fertilization, treating congenital anomalies associated with infertility, as well as endometriosis and polycystic ovarian syndrome. Noted for excellence in her field and a “Top Doctor, Atlanta 2019 and 2020″ she delivers lectures across the country and has published more than a dozen papers on reproduction and fertility. She is an active member of the American Society of Reproductive Medicine (ASRM) as well as the Georgia OB GYN Society. Note that INVO Bioscience has also signed clinic partnerships in Birmingham, Alabama and the San Francisco Bay area earlier this year, along with its Mexico partnership in late 2020, which is scheduled to open later this year. These clinics, through the utilization of the INVOcell technology, in addition to the multiple clinic and distribution partnerships throughout the world are bringing advanced fertility care and much needed expanded access to the millions of underserved people.
    • On June 15th, INVO Bioscience, Inc. (NASDAQ: INVO), announced further foundational progress as they appointed of Andrea Goren as the Company’s Chief Financial Officer. In a career approaching 27 years, Mr. Goren has extensive experience in numerous financial functions, including service as a public company CFO, company director, capital raising activities as well as mergers and acquisition experience. Mr. Goren has served as managing director and CFO of Phoenix Group, a New York City-based private equity firm specializing in micro-cap and nano-cap public companies. He served as vice president of Shamrock Group, the Roy Disney family private investment firm in London; and was a director at New York City-based Madison Capital Group, a corporate advisory firm focused on U.S. / European Union cross border transactions. Mr. Goren holds a Bachelor of Arts degree from Connecticut College in New London, Connecticut, and an MBA from the Columbia Business School in New York City.
    • On May 11, a 13G was filed that confirms that David Sable’s (a former #IVF doc turned portfolio manager) Special Situations Fund of AWM Investment Company increased their ownership to 11.1% or 1,154,153 share ownership of INVO Bioscience (INVO). They held 625k/6.5% as of the 13G filing 2-12-2021. If you are not familiar with them, I believe if you do a relatively small amount sleuthing you will find out that they are one of the most successful multi-billion funds over the last 20-years, especially in finding small undiscovered microchips. I believe that they led the round of $13M at $3.20 a share in November 12, 2020 that pushed INVO uplist to the NASDAQ. Here’s the 13G filing. The company only has 10,424,229 shares issued and outstanding as of March 31, 2021.
    • Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates. 

Markets

Symbol Name Last Price Change % Change

Big Movers

Symbol Name Last Price Change % Change

Bond Markets & US Dollar

Symbol Name Last Price Change % Change

Agriculture & Energy

Symbol Name Last Price Change % Change

Biotech & Healthcare

Symbol Name Last Price Change % Change

Consumer Goods & Trends

Symbol Name Last Price Change % Change

Financials & Fintech

Symbol Name Last Price Change % Change

Materials & Natural Resources

Symbol Name Last Price Change % Change

Technology & Beyond

Symbol Name Last Price Change % Change

Investing & Inspiration

  1. “You cannot escape the responsibility of tomorrow by evading it today.” – Abraham Lincoln
  2. “However difficult life may seem, there is always something you can do and succeed at.”– Stephen Hawking
  3. “Once you bring life into the world, you must protect it. We must protect it by changing the world.” – Elie Wiesel
  4. “Don’t let your ego get too close to your position, so that if your position gets shot down, your ego doesn’t go with it.” – Colin Powell
  5. “Good things do not come easy. The road is lined with pitfalls.” – Desi Arnaz
  6. Honoring the sacrifices many have made for our country in the name of freedom and democracy is the very foundation of Veterans Day.” – Charles B. Rangel,
  7. “The true sign of intelligence is not knowledge but imagination.” – Albert Einstein
  8. “Trust yourself, you know more than you think you do.” – Benjamin Spock
  9. “This idea of mutual appreciation and partnerships and investment in our people is very important to me and will continue to be important.” – Dennis Muilenburg
  10. “The true secret of happiness lies in taking a genuine interest in all the details of daily life.” – William Morris
  11. “Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn
  12. “Give me the luxuries of life and I will willingly do without the necessities.” – Frank Lloyd Wright
  13. “If opportunity doesn’t knock, build a door.” – Milton Berle
  14. “Age is an issue of mind over matter. If you don’t mind, it doesn’t matter.” – Mark Twain
  15. “The smallest deed is better than the greatest intention.” – John Burroughs
  16. “It’s the steady, quiet, plodding ones who win in the lifelong race.” – Robert W. Service
  17. “When I was young I thought that money was the most important thing in life; now that I am old I know that it is.” – Oscar Wilde
  18. “A savvy entrepreneur will not always look for investment money, first.” – Daymond John
  19. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  20. “Look deep into nature, and then you will understand everything better.” -Albert Einstein

  21. “The young man knows the rules, but the old man knows the exceptions.” – Oliver Wendell Holmes, Sr.

  22. “Don’t go through life, grow through life.”– Eric Butterworth
  23. “This life is worth living, we can say, since it is what we make it.” – William James
  24. “People who think they know everything are a great annoyance to those of us who do.” –  Isaac Asimov
  25. “True life is lived when tiny changes occur.”  – Leo Tolstoy
  26. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  27. “In order to attain the impossible, one must attempt the absurd.” – Miguel de Cervantes
  28. “Aim for the moon. If you miss, you may hit a star.” – W. Clement Stone
  29. “If I had to live my life again, I’d make the same mistakes, only sooner.” – Tallulah Bankhead
  30. “The deal machinations many companies put themselves through, while certainly a bonanza for investment bankers, can confound the typical investor.” – Whitney Tilson
  31. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  32. “Procrastination is the art of keeping up with yesterday.” – Don Marquis
  33. “Do not fear mistakes. You will know failure. Continue to reach out.” – Benjamin Franklin

  34. “Success is peace of mind which is a direct result of self-satisfaction in knowing you did your best to become the best you are capable of becoming.” – John Wooden
  35. “One fails forward toward success.” – Charles Kettering
  36. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  37. “I hear and I forget. I see and I remember. I do and I understand.” – Confucius
  38. “I’m a very strong believer in listening and learning from others.” – Ruth Bader Ginsburg
  39. “Blessed are those who give without remembering and take without forgetting.” – Elizabeth Bibesco
  40. “As you walk down the fairway of life you must smell the roses, for you only get to play one round.” – Ben Hogan
  41. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  42. “Economics is all about consumption. People either spend money now or they use financial instruments – like bonds, stocks and savings accounts – so they can spend more later.” – Adam Davidson
  43. “Ever tried. Ever failed. No matter. Try Again. Fail again. Fail better.” -Samuel Beckett
  44. “In the post-industrial economy, ideas and great minds often provide far greater return on investment than any other resources or capital investments.” – Marvin Ammori
  45. “Work like you don’t need the money. Love like you’ve never been hurt. Dance like nobody’s watching.” – Satchel Paige
  46. “One of the rules I’ve learned is that struggling to try and think your way into making an investment is usually the best way to not have a great outcome.” – Stephen A. Schwarzman
  47. “The secret of business is to know something that nobody else knows.” – Aristotle Onassis
  48. “It takes a long time to grow an old friend.” – John Leonard
  49. “Life is a dream for the wise, a game for the fool, a comedy for the rich, a tragedy for the poor.”– Sholom Aleichem
  50. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  51. “Man is only great when he acts from passion.” – Benjamin Disraeli
  52. “We need to stop thinking about infrastructure as an economic stimulant and start thinking about it as a strategy. Economic stimulants produce Bridges to Nowhere. Strategic investment in infrastructure produces a foundation for long-term growth.” – Roger McNamee
  53. “We must let go of the life we have planned, so as to accept the one that is waiting for us.” – Joseph Campbell
  54. “Put your heart, mind, and soul into even your smallest acts. This is the secret of success.” – Swami Sivananda
  55. “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” – Jimmy Dean
  56. “Companies have too many experts who block innovation. True innovation really comes from perpendicular thinking.” – Peter Diamandis
  57. “By failing to prepare, you are preparing to fail.” – Benjamin Franklin
  58. “We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein
  59. “When you’re an investor, you can look at the quantitative and qualitative elements of an investment, but there’s a third aspect: What you feel in your gut.” – Kevin O’Leary
  60. “Set your course by the stars, not by the lights of every passing ship.” – Omar N. Bradley
  61. “Do not take life too seriously. You will never get out of it alive.” – Elbert Hubbard
  62. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey 
  63. “Every good painter paints what he is.” – Jackson Pollock
  64. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  65. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  66. “You cannot have a positive life and a negative mind.” – Joyce Meyer 
  67. “Like wildebeest and zebra migration across the Serengeti, investment managers and consultants, too, have a habit of running together and, every now and then, changing direction.” – Sanjaya Baru
  68. “If people are anything but enthusiastic about the information or ideas that they’re sharing, they’re either not that invested in what they’re doing – or they’re not communicating that investment effectively.” – Ana Kasparian 
  69. “Life consists not in holding good cards but in playing those you hold well.” – Josh Billings 
  70. “Friend, there’s no greater investment in life than in being a people builder. Relationships are more important than our accomplishments.” – Joel Osteen
  71. “It’s only natural that the heavy users help contribute to the investment to keep the Web healthy. That is the most important concept of net neutrality.” – Lowell McAdam
  72. “The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul 
  73. “Eliminate emotion from your investment program.” -John C. Bogle

  74. “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.” – Ike Skelton
  75. “In every investment, before I get involved or invest, I always see what the mindset of the founder, the CEO, is.” – Zaza Pachulia
  76. “An investment said to have an 80% chance of success sounds far more attractive than one with a 20% chance of failure. The mind can’t easily recognize that they are the same.” – Daniel Kahneman
  77. “The return on investment in global health is tremendous, and the biggest bang for the buck comes from vaccines. Vaccines are among the most successful and cost-effective health investments in history.” – Seth Berkley
  78. “Few things in the world are more powerful than a positive push. A smile. A world of optimism and hope. A ‘you can do it’ when things are tough.” – Richard M. DeVos
  79. “To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” – Ralph Waldo Emerson
  80. “We all have dreams. But in order to make dreams come into reality, it takes an awful lot of determination, dedication, self-discipline, and effort.”  – Jesse Owens
  81. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward- American Writer, Born 1921
  82. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  83. “The secret of your future is hidden in your daily routine.” – Mike Murdock
  84.  “If somebody puts you down or criticizes you, just keep on believing in yourself and turn it into something positive.” – Leah LaBelle
  85. “Opportunity is missed by most people because it is dressed in overalls and looks like work”. -Thomas A. Edison
  86. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  87. “Human behavior flows from three main sources: desire, emotion, and knowledge.” – Plato

  88. “We are what our thoughts have made us; so take care about what you think. Words are secondary. Thoughts live; they travel far.” – Swami Vivekananda
  89. “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
  90. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll

  91. “Don’t worry about being a star, worry about doing good work, and all that will come to you.” – Ice Cube

  92. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

  93. Prediction is very difficult, especially if it’s about the future.” – Niels Bohr (Danish Physicist)
  94. “It is indeed true that the stock market can forecast the business cycle.” -Paul Samuelson

  95. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks

  96. “What lies behind you and what lies in front of you, pales in comparison to what lies inside of you.” – Ralph Waldo Emerson
  97. “Each new generation born is in effect an invasion of civilization by little barbarians, who must be civilized before it is too late.” – Thomas Sowell
  98. “Life is 10% what happens to you and 90% how you react to it.” – Charles R. Swindoll
  99. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  100. “View health as an investment, not an expense.” – John Quelch

  101. “Opportunity does not knock, it presents itself when you beat down the door.” – Kyle Chandler

  102. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll
  103. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  104. “That which does not kill us makes us stronger.” – Friedrich Nietzsche
  105. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  106. “A problem is a chance for you to do your best.”–  Duke Ellington
  107. “The best way to predict the future is to create it.” -Peter Drucker
  108. “I’m involved in the stock market, which is fun and, sometimes, very painful.” – Regis Philbin
  109. “Who owns the future? This is the question at the heart of every stock market.” – John Landgraf
  110. “One of the funny things about the stock market is that every time one person buys, another sells, and both think they are astute.” – William Feather
  111. While I’m sure some millennials are concerned with the ethical issues involved in mining for diamonds, the main reason they steer clear of the gems is because, well, they’re a dumb investment.” – Ana Kasparian
  112. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sack
  113. “We must shift our thinking away from short-term gain toward long-term investment and sustainability, and always have the next generations in mind with every decision we make.” –  Deb Haaland
  114. “The only way to have a friend is to be one.” –  Ralph Waldo Emerson
  115. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  116. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” -Liya Kebede

  117. “Success is not final, failure is not fatal: it is the courage to continue that counts.”– Winston Churchill
  118. “Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius

  119. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
  120. “Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
  121. “If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
  122. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
  123. “Start where you are. Use what you have. Do what you can.” – Arthur Ashe
  124. “Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger
  125. “When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn

  126. “No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
  127. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  128. “Modern medical advances have helped millions of people live longer, healthier lives.

  129. We owe these improvements to decades of investment in medical research.”– Ike Skelton

  130. “Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson

  131. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  132. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  133. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  134. “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
  135. “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
  136. “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
  137. “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
  138. “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
  139. “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
  140. “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
  141. “No stock price is too low for bears or too high for bulls.” – John F. Heerdink, Jr.
  142. “Investment is most successful when it is most businesslike.” – Ben Graham

  143. “Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne

  144. “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
  145. “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
  146. “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
  147. “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
  148. “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
  149. “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
  150. “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
  151. “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
  152. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  153. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  154. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  155. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  156. “Know what you own, and know why you own it.” – Peter Lynch
  157. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  158. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz
  159. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  160. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel
  161. “With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  162. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  163. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel

  164. “Never depend on a single income, make an investment to create a second source.” Warren Buffet

  165. Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
    ― Warren Buffett
  166. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  167. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  168. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  169. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  170. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  171. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  172. The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  173. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  174. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  175. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  176. “No Price is too low for a bear or too high for a bull.” — Anonymous
  177. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
  178. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  179. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  180. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  181. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  182. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  183. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  184. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  185. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  186. “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
  187. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  188. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  189. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  190. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  191. “Know what you own, and know why you own it.” – Peter Lynch
  192. “Liquidity is only there when you don’t need it.” -Old Proverb
  193. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  194. “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  195. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  196. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  197. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  198. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
  199. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  200. “An investment in knowledge pays the best interest.” – Benjamin Franklin.
  201. I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  202. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  203. “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  204. “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
  205. “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
  206. “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
  207. “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
  208. “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
  209. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  210. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  211. “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
  212. “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
  213. “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
  214. “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger
Symbol Name Last Price Change % Change

Videos

Please consider viewing these interesting videos: